CROSS or FLOT in Distal Esophageal and Gastroesophageal Cancer

J Coll Physicians Surg Pak. 2021 Mar;31(3):326-329. doi: 10.29271/jcpsp.2021.03.326.

Abstract

Objective: To compare the chemoradiotherapy for esophageal cancer followed by surgery study (CROSS) and continuous infusion 5-FU, leucovorin, oxaliplatin, and docetaxel (FLOT) protocols administered in distal esophageal and gastroesophageal junction (GEJ) tumors in terms of effectiveness and toxicity.

Study design: Descriptive study.

Place and duration of study: Ankara Oncology Training and Research Hospital, Turkey between 2015 and 2020.

Methodology: Patients diagnosed with distal esophageal and GEJ squamous cell carcinoma (SCC) or adenocarcinoma (ADC), older than 18 years of age, in localised or locally advanced stage were included. Metastatic stages were excluded. Kaplan-Meier was used for survival analysis, log-rank test was performed for comparisons between groups.

Results: A total of 25 patients (44.6%) were treated with CROSS protocol (15 distal esophageal and 10 GEJ tumor), 31 patients (55.4%) with GEJ tumors were treated with the FLOT regimen. Eight of the patients who were administered the CROSS protocol before the operation demonstrated complete pathologicial response, no patients in the FLOT group had complete response to the treatment. In patients with GEJ tumors and ADC histopathology, CROSS and FLOT group had similar second years survival (60% and 59.3%, respectively) (p = 0.803). The frequency of neutropenia was significantly higher in the CROSS group compared to the FLOT group (p = 0.004.) Conclusion: Postoperative pathological response rate in the CROSS group was significantly higher compared to the FLOT group. CROSS and FLOT protocols contributed to survival similarly in patients with GEJ ADC, hematological side effects were more pronounced in patients receiving CRT. Key Words: GEJ cancer, Esophageal cancer, Cross, Flot.

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Esophageal Neoplasms* / drug therapy
  • Esophagogastric Junction
  • Fluorouracil
  • Humans
  • Stomach Neoplasms* / therapy
  • Treatment Outcome
  • Turkey / epidemiology

Substances

  • Fluorouracil